Related Experiment Video

Updated: Jun 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice

Carlo Buonerba, Giovannella Palmieri, Giuseppe Di Lorenzo

    European Urology
    |June 29, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
    12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    Related Experiment Videos

    Last Updated: Jun 11, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
    12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Serum Trace Elements and Concurrent Renal, Hepatic, and Electrolyte Biomarkers: A Secondary Cross-Sectional Analysis of SPES.

    International journal of molecular sciences·2026

    [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

    Current oncology (Toronto, Ont.)·2026

    Stage-specific quality of life and tolerability of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer: a narrative review.

    Oncology·2026

    Associations of Serum Trace-Element Concentrations with Selected Blood Biomarkers: A Secondary Cross-Sectional Analysis of the SPES Cohort.

    Toxics·2026

    Serum Trace Elements and Self-Reported Physician-Diagnosed Tumor History: A Secondary Cross-Sectional Analysis of the Exposure Study on Susceptible People (SPES).

    Medicina (Kaunas, Lithuania)·2026

    Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series.

    Current oncology (Toronto, Ont.)·2026

    Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.

    European urology·2026

    Epidemiology, Risk Factors, and Prevention of Prostate Cancer.

    European urology·2026

    Surgery in Motion: Different Surgical Techniques for Inguinal Lymph Node Dissection in Penile Cancer.

    European urology·2026

    Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.

    European urology·2026

    177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.

    European urology·2026

    Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.

    European urology·2026

    Visualization of Changes in the Kidneys, Testes, Ovaries, and Uterus of Rats During Plastination, and Their Evaluation by SEM and Histology.

    Veterinary sciences·2026

    sDR5-Fc Administered Post-Exposure Alleviates Radiation-Induced Enteric Injury by Inhibiting ROS and NLRP3/Caspase-1/GSDMD-Dependent Pyroptosis and Inflammatory Response.

    Pharmaceuticals (Basel, Switzerland)·2026

    Dosimetry Data Infrastructure for Individualized Radiopharmaceutical Therapy: International Experience and a Proposed Framework for China.

    Pharmaceuticals (Basel, Switzerland)·2026

    Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [177Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling.

    Pharmaceutics·2026

    Early CYNC-1 Administration Attenuates Radiation-Induced Lung Inflammation and Subsequent Fibrotic Remodeling.

    Pharmaceutics·2026

    Development of a GRPR-Targeted 99mTc/188Re Theranostic Pair Based on NOTA-P2-RM26.

    Pharmaceutics·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us